Compared with the adjuvant-free mRNA vaccine NP, the mRNA vaccine NP regimen pulsed with C16-R848 adjuvant significantly improved the expansion of OVA-specific CD8+T cells in vivo and their invasion to the tumor bed, and induced a strong adaptive immune response 32. This evidence concerns the gene CD8A and neoplasm.